T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation

Abstract

A vaccine contains a long-chain peptide antigen having a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains two to ten consecutive tyrosines, two to ten consecutive threonines, two to ten consecutive alanines, two to ten consecutive histidines, two to ten consecutive glutamines or two to ten consecutive asparagines. The vaccine may be an anticancer vaccine, an antibacterial vaccine or an antiviral vaccine. The vaccine may be a peptide vaccine, a DNA vaccine, an mRNA vaccine or a dendritic cell vaccine.

1 . A vaccine including a long chain peptide antigen having a plurality of epitopes in which each interepitope sequence is one selected from a group consisting of two to ten consecutive tyrosines, two to ten consecutive threonines, two to ten consecutive alanines, two to ten consecutive histidines, two to ten consecutive glutamines and two to ten consecutive asparagines. 
     
     
         2 . The vaccine as claimed in  claim 1 , which is one selected from a group consisting of anticancer vaccines, antibacterial vaccines and antiviral vaccines. 
     
     
         3 . The vaccine as claimed in  claim 2 , which is one selected from a group consisting of peptide vaccines, DNA vaccines, mRNA vaccines and dendritic cell vaccines. 
     
     
         4 . The vaccine as claimed in  claim 3 , wherein the interepitope sequence is one selected from a group consisting of four to eight consecutive tyrosines, four to eight consecutive glutamines and four to eight consecutive asparagines. 
     
     
         5 . The vaccine as claimed in  claim 3 , wherein the interepitope sequence is one selected from a group consisting of six consecutive tyrosines, six consecutive glutamines and six consecutive asparagines. 
     
     
         6 . The vaccine as claimed in  claim 4 , which is an anticancer vaccine and a peptide vaccine. 
     
     
         7 . The vaccine as claimed in  claim 4 , which contains a plurality of long chain peptide antigens. 
     
     
         8 . A combination vaccine which contains the vaccine as claimed in  claim 7  and a hydrophobized polysaccharide as a delivery system. 
     
     
         9 . The vaccine as claimed in  claim 8 , wherein the hydrophobized polysaccharide is cholesterol-modified pullulan (CHP). 
     
     
         10 . A method of treating a patient in need thereof, comprising administering to the patient the vaccine of  claim 9 . 
     
     
         11 . A method of treating a patient in need thereof, comprising administering to the patient the vaccine of  claim 1 . 
     
     
         12 . The vaccine as claimed in  claim 1 , which is one selected from a group consisting of peptide vaccines, DNA vaccines, mRNA vaccines and dendritic cell vaccines. 
     
     
         13 . The vaccine as claimed in  claim 1 , wherein the interepitope sequence is one selected from a group consisting of four to eight consecutive tyrosines, four to eight consecutive glutamines and four to eight consecutive asparagines. 
     
     
         14 . The vaccine as claimed in  claim 1 , wherein the interepitope sequence is one selected from a group consisting of six consecutive tyrosines, six consecutive glutamines and six consecutive asparagines. 
     
     
         15 . The vaccine as claimed in  claim 1 , which is an anticancer vaccine and a peptide vaccine. 
     
     
         16 . The vaccine as claimed in  claim 1 , which contains a plurality of long chain peptide antigens. 
     
     
         17 . A combination vaccine which contains the vaccine as claimed in  claim 1  and a hydrophobized polysaccharide as a delivery system. 
     
     
         18 . The vaccine as claimed in  claim 17 , wherein the hydrophobized polysaccharide is cholesterol-modified pullulan (CHP).